Stable oxyntomodulin analogues exert positive effects on hippocampal neurogenesis and gene expression as well as improving glucose homeostasis in high fat fed mice

Molecular and Cellular Endocrinology

Volumn 412, Issue , 2015, Pages 95-103

  Pathak, N M ^a   Pathak, V ^a   Lynch, A M ^a   Irwin, N ^a   Gault, V A ^a   Flatt, P R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Cognition; Glucagon like peptide 1; Hippocampus; Oxyntomodulin; Oxyntomodulin analogues

Indexed keywords

8 HYDROXYGUANINE; DOUBLECORTIN; FAT; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; OXYNTOMODULIN; SIRTUIN 1; SODIUM CHLORIDE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR MASH1; (DS2)OXM(K-GAMMA-GLU-PAL); ANTIDIABETIC AGENT; DOUBLECORTIN PROTEIN; GASTROINTESTINAL HORMONE; GLUCOSE BLOOD LEVEL; MICROTUBULE ASSOCIATED PROTEIN; NEUROPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; BRAIN CORTEX; CALORIC INTAKE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HIPPOCAMPUS; HISTOLOGY; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; LIPID DIET; MALE; METABOLIC REGULATION; MOUSE; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SYNAPTOGENESIS; UPREGULATION; WEIGHT REDUCTION; ADVERSE EFFECTS; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG STABILITY; HOMEOSTASIS; LIPID METABOLISM; METABOLISM; NERVOUS SYSTEM DEVELOPMENT; OBESITY; PANCREAS; PATHOLOGY; PRECLINICAL STUDY; SECRETION (PROCESS);

ADIPOSITY; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; ENERGY INTAKE; GASTROINTESTINAL HORMONES; GENE EXPRESSION; HIPPOCAMPUS; HOMEOSTASIS; HYPOGLYCEMIC AGENTS; INSULIN; LIPID METABOLISM; MALE; MICE; MICROTUBULE-ASSOCIATED PROTEINS; NEUROGENESIS; NEUROPEPTIDES; OBESITY; PANCREAS;

EID: 84934990816     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.05.035     Document Type: Article

References (61)

1. Alvarez E., Roncero I., Chowen J.A., Thorens B., Blázquez E. Expression of the glucagon-like peptide-1 receptor gene in rat brain. J. Neurochem 1996, 66:920-927.
2. Baggio L.L., Huang Q., Brown T.J., Drucker D.J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004, 127:546-558.
3. Bataille D., Dalle S. The forgotten members of the glucagon family. Diabetes Res. Clin. Pract 2014, 106:1-10.
4. Bataille D., Gespach C., Tatemoto K., Marie J.C., Coudray A.M., Rosselin G., et al. Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides 1981, 2(S2):41-44.
5. Bianchi E., Carrington P.E., Ingallinella P., Finotto M., Santoprete A., Petrov A., et al. A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycaemic, insulinotropic and anorexigenic activity. Bioorg. Med. Chem 2013, 21:7064-7073.
6. Bozdagi O., Shan W., Tanaka H., Benson D.L., Huntley G.W. Increasing numbers of synaptic puncta during late-phase LTP: N-cadherin is synthesized, recruited to synaptic sites, and required for potentiation. Neuron 2000, 28:245-259.
7. Campos R.V., Lee Y.C., Drucker D.J. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994, 134:2156-2164.
8. Deng W., Aimone J.B., Gage F.H. New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?. Nat. Rev. Neurosci 2010, 11:339-350.
9. Druce M.R., Minnion J.S., Field B.C., Patel S.R., Shillito J.C., Tilby M., et al. Investigation of structure-activity relationships of oxyntomodulin (Oxm) using Oxm analogs. Endocrinology 2009, 150:1712-1722.
10. Du X., Kosinski J.R., Lao J., Shen X., Petrov A., Chicchi C.G., et al. Differential effects of oxyntomodulin and GLP-1 on glucose metabolism. Am. J. Physiol. Endocrinol. Metab 2012, 303:265-271.
11. Dunphy J.L., Taylor R.G., Fuller P.J. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol. Cell. Endocrinol 1998, 141:179-186.
12. Flatt P.R., Bailey C.J. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 1981, 20:573-577.
13. Garcia-Casares N., García-Arnés J.A., Gómez-Huelgas R., Valdivielso-Felices P., Garcóa-Arias C., González-Santos P. Glucagon-like peptide-1 (GLP-1) mimetics: a new treatment for Alzheimer's disease?. Rev. Neurol 2014, 59:517-524.
14. Gault V.A., Porter W.D., Flatt P.R., Hölscher C. Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet. Int. J. Obes. (Lond) 2010, 34:1341-1344.
15. Gault V.A., Lennox R., Flatt P.R. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes Obes. Metab 2015, 17:403-413.
16. Gual P., Le Marchand-Brustel Y., Tanti J.F. Positive and negative regulation of insulin signalling through IRS-1 phosphorylation. Biochimie 2005, 87:99-109.
17. Hamilton A., Hölscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport 2009, 20:1161-1166.
18. Holst J.J. Enteroglucagon. Annu. Rev. Physiol 1997, 59:257-271.
19. Hoosein N.M., Gurd R.S. Identification of glucagon receptors in rat brain. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:4368-4372.
20. Hölscher C. New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases. Neural Regen. Res 2014, 9:1870-1873.
21. Irwin N., Flatt P.R. Enteroendocrine hormone mimetics for the treatment of obesity and diabetes. Curr. Opin. Pharmacol 2013, 13:989-995.
22. Isacson R., Nielsen E., Dannaeus K., Bertilsson G., Patrone C., Zachrisson O., et al. The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharmacol 2011, 650:249-255.
23. Jaeger S., Pietrzik C.U. Functional role of lipoprotein receptors in Alzheimer's disease. Curr. Alzheimer Res 2008, 5:15-25.
24. Kerr B.D., Flatt P.R., Gault V.A. (d-Ser2)Oxm[mPEG-PAL]: a novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions. Biochem. Pharmacol 2010, 80:1727-1735.
25. Kim B., Feldman E.L. Insulin resistance as a key link for the increased cognitive impairment in the metabolic syndrome. Exp. Mol. Med 2015, 47:e149.
26. Kosaraju J., Murthy V., Khatwal R.B., Dubala A., Chinni S., Muthureddy Nataraj S.K., et al. Vildagliptin: an anti-diabetes agent ameliorates cognitive decline and pathology observed in streptozotocin-induced Alzheimer's disease. J. Pharm. Pharmacol 2013, 65:1773-1784.
27. Kwon S.E., Chapman E.R. Synaptophysin regulates the kinetics of synaptic vesicle endocytosis in central neurons. Neuron 2011, 70:847-854.
28. LaFerla F.M., Oddo S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol. Med 2005, 11:170-176.
29. Lennox R., Porter D.W., Flatt P.R., Gault V.A. (Val8)GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and beta-cell function in high-fat-fed mice. ChemMedChem 2013, 8:595-602.
30. Lennox R., Flatt P.R., Gault V.A. Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice. Peptides 2014, 61:38-47.
31. Lennox R., Porter D.W., Flatt P.R., Hölscher C., Irwin N., Gault V.A. Comparison of the independent and combined effects of sub-chronic therapy with metformin and a stable GLP-1 receptor agonist on cognitive function, hippocampal synaptic plasticity and metabolic control in high-fat fed mice. Neuropharmacology 2014, 86:22-30.
32. Liu Y., Palanivel R., Rai E., Park M., Gabor T.V., Scheid M.P., et al. Adiponectin stimulates autophagy and reduces oxidative stress to enhance insulin sensitivity during high fat diet feeding in mice. Diabetes 2014, 64:36-48.
33. Liu Y.L., Ford H.E., Druce M.R., Minnion J.S., Field B.C., Shillito J.C., et al. Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. Int. J. Obes. (Lond) 2010, 34:1715-1725.
34. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
35. Lynch A.M., Pathak N., Flatt Y.E., Gault V.A., O'Harte F.P., Irwin N., et al. Comparison of stability, cellular, glucose-lowering and appetite suppressing effects of oxyntomodulin analogues modified at the N-terminus. Eur. J. Pharmacol 2014, 743:69-78.
36. Maida A., Lovshin J.A., Baggio L.L., Drucker D.J. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology 2008, 149:5670-5678.
37. Marcello E., Epis R., Saraceno C., Di Luca M. Synaptic dysfunction in Alzheimer's disease. Adv. Exp. Med. Biol 2012, 970:573-601.
38. McNay E.C., Recknagel A.K. Brain insulin signaling: a key component of cognitive processes and a potential basis for cognitive impairment in type 2 diabetes. Neurobiol. Learn. Mem 2011, 96:432-442.
39. Merchenthaler I., Lane M., Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J. Comp. Neurol 1999, 403:261-280.
40. Michán S., Li Y., Chou M.M., Parrella E., Ge H., Long J.M., et al. SIRT1 is essential for normal cognitive function and synaptic plasticity. J. Neurosci 2010, 30:9695-9707.
41. Moffett R.C., Patterson S., Irwin N., Flatt P.R. Positive effects of GLP-1 receptor activation with liraglutide on pancreatic islet morphology and metabolic control in C57BL/KsJ db/db mice with degenerative diabetes. Diabetes Metab. Res. Rev 2015, 31:248-255.
42. Monte S.M. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res 2012, 9:35-66.
43. Parker J.A., McCullough K.A., Field B.C., Minnion J.S., Martin N.M., Ghatie M.A., et al. Glucagon and GLP-1 inhibit food intake and increase c-fos expression in similar appetite regulating centres in the brainstem and amygdala. Int. J. Obes. (Lond) 2013, 37:1391-1398.
44. Patrone C., Eriksson O., Lindholm D. Diabetes drugs and neurological disorders: news views and therapeutic possibilities. Lancet Diabetes Endocrinol 2014, 2:256-262.
45. Pintana H., Apaijai N., Chattipakorn N., Chattipakorn S.C. DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J. Endocrinol 2013, 218:1-11.
46. Pipatpiboon N., Pintana H., Pratchayasakul W., Chattipakorn N., Chattipakorn S.C. DPP-4 inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. Eur. J. Neurosci 2013, 37:839-849.
47. Pocai A. Action and therapeutic potential of oxyntomodulin. Mol. Metab 2013, 3:241-251.
48. Porter D.W., Kerr B.D., Flatt P.R., Hölscher C., Gault V.A. Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes Obes. Metab 2010, 12:891-899.
49. Porter W.D., Flatt P.R., Hölscher C., Gault V.A. Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice. Int. J. Obes. (Lond) 2013, 37:678-684.
50. Praticò D., Clark C.M., Liun F., Rokach J., Lee V.Y., Trojanowski J.Q. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer's disease. Arch. Neurol 2002, 59:972-976.
51. Rao M.S., Shetty A.K. Efficacy of doublecortin as a marker to analyse the absolute number and dendritic growth of newly generated neurons in the adult dentate gyrus. Eur. J. Neurosci 2004, 19:234-246.
52. Santoprete A., Capito E., Carrington P.E., Pocai A., Finotto M., Langella A., et al. DPP-IV resistant, long-acting oxyntomodulin derivatives. J. Pept. Sci 2011, 17:270-280.
53. Schepp W., Dehne K., Riedel T., Schmidtler J., Schaffer K., Classen M. Oxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36)NH2. Digestion 1996, 57:398-405.
54. Schmitt U., Tanimoto N., Seeliger M., Schaeffel F., Leube R.E. Detection and behavioural alterations and learning deficits in mice lacking synaptophysin. Neuroscience 2009, 162:234-243.
55. Sommer L., Shah N., Rao M., Anderson D.J. The cellular function of MASH1 in autonomic neurogenesis. Neuron 1995, 15:1245-1258.
56. Steen E., Terry B.M., Rivera E.J., Cannon J.L., Neely T.R., Tavares R., et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes?. J. Alzheimers Dis 2005, 7:63-80.
57. Talbot K. Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. Neurodegener. Dis. Manag 2014, 4:31-40.
58. Vasu S., Moffett R.C., McCluskey J.T., Hamid M.H., Irwin N., Flatt P.R. Beneficial effects of parenteral GLP-1 delivery by cell therapy in insulin-deficient streptozotocin diabetic mice. Gene Ther 2013, 20:1077-1084.
59. Wang Y., Xu X.Y., Feng C.H., Li Y.L., Ge X., Zong G.L., et al. Patients with type 2 diabetes exhibit cognitive impairment with changes of metabolite concentration in the left hippocampus. Metab. Brain Dis 2015, Epub ahead of print.
60. Wynne K., Bloom S.R. The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control. Nat. Clin. Pract. Endocrinol. Metab 2006, 2:612-620.
61. Zhu L., Tamvakopoulos C., Xie D., Dragovic J., Shen X., et al. The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38). J. Biol. Chem 2003, 278:22418-22423.